Juvenile Dermatomyositis clinical trials at UCSF
1 research study open to eligible people
Showing trials for
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
open to eligible people ages 6-75
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
San Francisco, California and other locations
Our lead scientists for Juvenile Dermatomyositis research studies include Susan Kim, MD, MMSc.
Last updated: